Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr;36(4):747-761.
doi: 10.1007/s00467-020-04476-9. Epub 2020 Feb 21.

Current understandings in treating children with steroid-resistant nephrotic syndrome

Jiwon M Lee  1 , Andreas Kronbichler  2 , Jae Il Shin #  3   4   5 , Jun Oh #  6
Affiliations
Review

Current understandings in treating children with steroid-resistant nephrotic syndrome

Jiwon M Lee et al. Pediatr Nephrol. 2021 Apr.

Abstract

Steroid-resistant nephrotic syndrome (SRNS) remains a challenge for paediatric nephrologists. SRNS is viewed as a heterogeneous disease entity including immune-based and monogenic aetiologies. Because SRNS is rare, treatment strategies are individualized and vary among centres of expertise. Calcineurin inhibitors (CNI) have been effectively used to induce remission in patients with immune-based SRNS; however, there is still no consensus on treating children who become either CNI-dependent or CNI-resistant. Rituximab is a steroid-sparing agent for patients with steroid-sensitive nephrotic syndrome, but its efficacy in SRNS is controversial. Recently, several novel monoclonal antibodies are emerging as treatment option, but their efficacy remains to be seen. Non-immune therapies, such as angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, have been proven efficacious in children with SRNS and are recommended as adjuvant agents. This review summarizes and discusses our current understandings in treating children with idiopathic SRNS.

Keywords: Children; Intractable; Monogenic; Nephrotic syndrome; Resistant; Treatment.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Eddy AA, Symons JM. Nephrotic syndrome in childhood. Lancet. 2003;362:629–639. - PubMed
    1. Franke I, Aydin M, Kurylowicz L, Lopez CEL, Ganschow R, Lentze MJ, Born M. Clinical course & management of childhood nephrotic syndrome in Germany: a large epidemiological ESPED study. BMC Nephrol. 2019;20:45. - PMC - PubMed
    1. Franke I, Aydin M, Llamas Lopez CE, Kurylowicz L, Ganschow R, Lentze M, Born M. The incidence of the nephrotic syndrome in childhood in Germany. Clin Exp Nephrol. 2018;22:126–132. - PubMed
    1. Dossier C, Lapidus N, Bayer F, Sellier-Leclerc AL, Boyer O, de Pontual L, May A, Nathanson S, Orzechowski C, Simon T, Carrat F, Deschenes G. Epidemiology of idiopathic nephrotic syndrome in children: endemic or epidemic? Pediatr Nephrol. 2016;31:2299–2308. - PubMed
    1. Nandlal L, Naicker T, Bhimma R. Nephrotic syndrome in South African children: changing perspectives in the new millennium. Kidney Int Rep. 2019;4:522–534. - PMC - PubMed

Publication types

LinkOut - more resources